Evidence map›Paper›PMID 38267866›Full record

Trial reportBMC cancer2024

Long-term outcomes with HLX01 (HanliKang

Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang and 18 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Biosimilar monoclonal antibodies for cancer treatment in adults.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  4. Cost-effectiveness of HLX01 (HanlikangFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 1 country.

Yan QinDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China.
Yongping SongDepartment of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dong WangDepartment of Oncology, Army Characteristic Medical Center, Chongqing, China.
Ou BaiDepartment of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China.
Jifeng FengDepartment of Oncology, Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China.
Xiuhua SunDepartment of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Lihua QiuDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China.
Jianmin YangDepartment of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yu YangDepartment of Lymphoma & Head and Neck Tumors, Fujian Medical University Cancer Hospital, Fuzhou, China.
Zhao WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jianda HuDepartment of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Huaqing WangDepartment of Medical Oncology, Tianjin Union Medical Centre of Nankai University, Tianin, China.
Hang SuDepartment of Lymphoma, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhengming JinDepartment of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Wenbin QianDepartment of Hematology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chuan JinDepartment of Oncology, Guangzhou Medical University, Guangzhou, China.
Mingzhi ZhangDepartment of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ding YuDepartment of Oncology Medicine, Hubei Cancer Hospital, Wuhan, China.
Li LiuDepartment of Hematology, the Second Affiliated Hospital of Air Force Medical University (Tangdu Hospital), Xian, China.
Guoan ChenDepartment of Hematology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Yarong LiHematology and Oncology Department, the Second Hospital of Jilin University, Changchun, China.
Tao SunDepartment of Breast Medicine, Liaoning Cancer Hospital, Shenyang, China.
Jie JinDepartment of Hematology, the First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China.
Huizheng BaoDepartment of Lymphology and Hematology, Jilin Provincial Cancer Hospital, Changchun, China.
Xin DuDepartment of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China.
Hui ZhouDepartment of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China.
Gan FuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Yuankai ShiDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China. syuankai@cicams.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Zhengzhou University · CNFujian Medical University · CNAir Force Medical University · CNBeijing Friendship Hospital · CNCentral South University · CNChanghai Hospital · CNChinese PLA General Hospital · CNFirst Affiliated Hospital of Nanchang University · CNFirst Affiliated Hospital of Soochow University · CNGuangdong Provincial People's Hospital · CNGuangzhou Medical University · CNHubei Cancer Hospital · CNHunan Cancer Hospital · CNJilin Province Tumor Hospital · CNJilin University · CNLiaoning Cancer Hospital & Institute · CNNanjing Medical University · CNNankai University · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLX01 (HanliKang

Indexed as

Biosimilar PharmaceuticalsLymphoma, Large B-Cell, DiffuseCyclophosphamideDoxorubicinFollow-Up StudiesHumansPrednisoneRituximabBiosimilar PharmaceuticalsCyclophosphamideDoxorubicinPrednisoneRituximabDLBCLHanliKang®HLX01Overall survivalRituximab biosimilar

Identifiers

PMID38267866
PMCPMC10809427
OpenAlexW4391211320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.